The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2022 | How NK therapies are transforming the treatment landscape of Hodgkin lymphoma
Yago Nieto, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the promise of novel natural killer (NK) therapies in the treatment of Hodgkin lymphoma (HL). Prof. Nieto first explains the role of brentuximab vedotin in the treatment of HL, and the need provide more options for patients who relapse or do not respond to this therapy. Prof. Nieto then explains the benefits of using NK cells, including the high activity and safety profiles demonstrated in various studies. To conclude, Prof. Nieto highlights the lower cost associated with manufacturing NK cells, as well as their ability to target various tumors. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.
